Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1

Summary

This is a single arm phase II trial enrolling patients with stage II-IIIA non-small cell lung cancer whose disease is deemed amenable for surgical resection and has a PD-L1 level of ≥50%. Patients will receive cemiplimab for 3 cycles followed by surgical resection. The primary endpoint evaluated by the study is the amount of residual tumor in the resected tissue after 3 cycles of cemiplimab. After surgery, all patients will receive additional 10 cycles of cemiplimab and the treating oncologist will decide on the need of administering chemotherapy prior to that.

Timeline

Start

2027-01-01

Primary completion

2027-12-01

Completion

2027-12-01

Drugs

Indications